IMMUNOME, INC. - SCHEDULE 13D/A Filing Summary

This filing is an amendment to a previous Schedule 13D, reporting a dilution in beneficial ownership of IMMUNOME, INC. common stock by Enavate Sciences GP, LLC and Immunome Aggregator, LP. The dilution is not due to any acquisition or disposition of securities but rather an increase in the total number of outstanding shares. The reporting entities ceased to be beneficial owners of more than five percent of the common stock on December 18, 2025. The ownership percentage is calculated based on 91,710,277 shares outstanding as of November 3, 2025, plus 18,625,000 shares issued in a public offering that closed on December 18, 2025. Enavate Sciences GP, LLC and Immunome Aggregator, LP collectively hold 4,768,583 shares, representing 4.3% of the class, with shared voting and dispositive power.